Comprehensive Liquid Biopsy – When Next?

Ran On Tuesday, September 22 | 12pm EST

Engage News & Brews
hosted by...

Guardant

Free To Attend!

This online Guardant Health Engager is part of an exclusive event series providing leaders in pharma and biotech an opportunity to explore the latest insights and innovations facilitating the advancement of precision medicine.

These popular events have been adapted to a virtual format, so you can forge connections with key company and industry thought leaders and learn about diagnostic advances that have the potential to expedite end-to-end drug development, from the comfort of your own home.

Join Guardant Health for an exploration into:

Comprehensive Liquid Biopsy – When Next?

Guardant

Join Guardant Health and guest speaker, Clara Montagut from Hospital Del Mar, Spain, as they take you on a deep dive into the new, emerging and transformative opportunities liquid biopsy applications hold for the future of cancer care.

With recent FDA approvals highlighting the patient stratification and predictive power of these technologies, expect to be equipped with latest expert insight on applying such techniques to see more robust clinical outcomes.

Key Topics Included:  

  • An update on the recent Guardant360 FDA approval
  • Future opportunities for faster, cost effective and patient-centric liquid biopsy approaches in clinical programs
  • Evaluation of liquid biopsy approaches in early detection and MRD settings in clinical practice
  • Data-driven insights from RWE utilizing in silico models to detect genomic changes over time, including therapeutic response and resistance

Following a live Q&A, feel free to stay and mingle with the speakers, members of Guardant Health and your local precision oncology peers to debate and discuss your biggest challenges, providing you with practical takeaways to streamline your workflows.

Who should attend?

This was an event for senior executives from drug development organizations looking to refine trial design, increase identification of patient responders and accelerate delivery of the next generation of targeted therapies in areas of high unmet need.

Should you have any questions, please reach out to dominic.allen@hansonwade.com and we will be in touch!

Your Speakers